Archives: Speakers

Angela Luttick is a virologist with more than 20 years’ experience in the discovery, development and commercialisation of novel drugs. Well accustomed to leading multidisciplinary teams and experienced in the generation and integrity of key discovery-stage biological data required for the preparation of IND packages used in filing numerous FDA submissions. Angela is a co-founder and executive director at 360biolabs and leads business development and strategy for company growth.

Cameron Johnson is considered one of the most experienced Phase I Clinical Trial professionals in Australia, having held senior management roles within three of the four established Phase I Australian Clinical Trial companies.

Cameron’s Phase I experience extends into Europe and the Clinical Research Organization (CRO) industry, where he managed Clinical Trial facilities across Australia and New Zealand. He joined Nucleus Network in September 2013 as Chief Operating Officer before moving into the position of Chief Executive Officer (CEO) in May 2016.

Dr. Sara De Pelsmaeker graduated as a Bio-Engineer in Food Technology and Nutrition in 2009 at Ghent University. She obtained her Doctoral Degree in Applied Biological Sciences in 2016 at Ghent University with an expertise in sensory analysis. During her PhD at the department Agricultural Economics she gained extensive knowledge on business development and economics.

She started her career at the Coca-Cola Company where she worked as sensory specialist EMEA and in R&D focusing on adult sparkling drinks.

Since 2018 she has joined Rousselot as a Product and Business Development Manager to support the Rousselot business in North-West Europe. Since 2019, she is focusing on the business development of our Health & Nutrition segment in EMEA. In her role, she works together with existing and potential customer to find the perfect solution for new collagen based launches.

John has 15+ years of experience in the medical device and pharmaceutical industry with responsibility for people management/development, global clinical trial management, regulatory strategy, and leading product development processes with emphasis on comprehensive regulatory and clinical strategy and product risk management. John’s experience in clinical and regulatory includes leading multiple Investigational Device Exemption IDE Trials, regulatory submissions, and FDA communications in a variety of indications including spine, neurosurgical, cranial, pulmonology, gastroenterology, diagnostics (IVDs), women’s health, and vascular surgery devices.